February 6, 2017Open Access

Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells

Key Points

Key points are not available for this paper at this time.

Abstract

This targeted and pH-sensitive controlled drug delivery system has the potential for promising application to enhance the therapeutic index and reduce the side effects of B cell lymphoma therapy.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Zhou et al. (Mon,) studied this question.

synapsesocial.com/papers/69dd3a761e42b7f8aa100e20 https://doi.org/https://doi.org/10.1186/s13046-017-0492-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Hyaluronic Acid Oligosaccharide Modified Redox-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery2014 · 147 citations
2Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves2010 · 588 citations
3Enzyme‐Responsive Cell‐Penetrating Peptide Conjugated Mesoporous Silica Quantum Dot Nanocarriers for Controlled Release of Nucleus‐Targeted Drug Molecules and Real‐Time Intracellular Fluorescence Imaging of Tumor Cells2014 · 152 citations
4Near-Infrared-Triggered Anticancer Drug Release from Upconverting Nanoparticles2014 · 112 citations
5Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction2015 · 51 citations

AI에게 질문

Bookmark

View Full Paper